Health
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., October 18, 2025--ENHERTU Reduced Risk of Disease Recurrence or Death by 53% vs. T-DM1 in High-Risk HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/d403b919df30856b409be8a8e6e2bbe1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bs.xrElaQZjF3QNDGtwD3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d403b919df30856b409be8a8e6e2bbe1","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside DESTINY-Breast11 reinforces potential for ENHERTU to become a foundational treatment in curative-intent early breast cancer setting","length":201,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":325,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 18, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented today (LBA1) alongside the results of DESTINY-Breast11 (291O) in Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.","length":756,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NASDAQ: AZN).","length":229,"tagName":"p"},{"type":"text","content":"In the primary endpoint analysis, ENHERTU significantly reduced the risk of invasive disease recurrence or death (invasive disease-free survival [IDFS]) by 53% (hazard ratio [HR]=0.47; 95% confid...